248 GSK Annual Report 2017 Financial record continued Five year record A record of financial performance is provided, analysed in accordance with current reporting practice.
The information included in the Five year record is prepared in accordance with IFRS as adopted by the European Union and also with IFRS as issued by the International Accounting Standards Board.
Comparative information for 2013 is also reported including the effect of the divestments completed in 2013.
The number of employees is the number of permanent employed staff at the end of the financial period.
It excludes those employees who are employed and managed by GSK on a contract basis.
Exchange rates As a guide to holders of ADS, the following tables set out, for the periods indicated, information on the exchange rate of US Dollars for Sterling as reported by the Bank of England 4pm buying rate.
The average rate for the year is calculated as the average of the 4pm buying rates for each day of the year.
251 GSK Annual Report 2017 Strategic report Governance and remuneration Financial statements Investor information Pipeline, products and competition Pharmaceuticals and Vaccines product development pipeline Key In-licence or other alliance relationship with third party MAA Marketing Authorisation Application Europe V iiV Healthcare, a global specialist HIV company with NDA New Drug Application US GSK, Pfizer, Inc. and Shionogi Limited as shareholders, Phase I Evaluation of clinical pharmacology, usually conducted is responsible for developing and delivering HIV medicines.
in volunteers 1 Option-based alliance with Ionis Pharmaceuticals, Inc.
Phase II Determination of dose and initial evaluation of efficacy, S Month of first submission conducted in a small number of patients A Month of first regulatory approval for MAA, this is the first Phase III Large comparative study compound versus placebo EU approval letter and or established treatment in patients to establish BLA Biological Licence Application clinical benefit and safety MAA and NDA BLA regulatory review milestones shown in the table below are those that have been achieved.
Future filing dates are not included in this list.
Achieved regulatory review milestones Compound Type Indication Phase MAA NDA BLA HIV and Infectious Diseases dolutegravir HIV integrase strand transfer inhibitor nonHIV infection virologically suppressed patients Approved S: May17 A: Nov17 rilpivirine nucleoside reverse transcriptase inhibitor NNRTI tafenoquine 8-aminoquinoline plasmodium vivax malaria Submitted S: Nov17 Dectova zanamivir i. v. neuraminidase inhibitor i. v. influenza Submitted S: Nov17 dolutegravir HIV integrase strand transfer inhibitor nucleoside HIV infection III lamivudine reverse transcriptase inhibitor NRTI fostemsavir HIV attachment inhibitor HIV infection III cabotegravir HIV integrase strand transfer inhibitor long-acting HIV pre-exposure prophylaxis III cabotegravir HIV integrase strand transfer inhibitor nonHIV infection III rilpivirine nucleoside reverse transcriptase inhibitor NNRTI long-acting regimen gepotidacin type 2 topoisomerase inhibitor bacterial infections II 2140944 1 3228836 HBV antisense oligonucleotide hepatitis B II 1 3389404 HBV LICA antisense oligonucleotide hepatitis B II CCI15106 viral replication inhibitor nucleoside viral exacerbations of COPD I 3640254 HIV maturation inhibitor HIV infection I 3036656 leucyl t-RNA synthetase inhibitor tuberculosis I Respiratory mepolizumab interleukin 5 IL5 monoclonal antibody eosinophilic granulomatosis with polyangiitis Approved A:Dec17 Trelegy fluticasone glucocorticoid agonist long-acting beta2 chronic obstructive pulmonary disease COPD Approved A:Nov17 A:Sep17 furoate vilanterol agonist muscarinic acetylcholine antagonist umeclidinium mepolizumab interleukin 5 IL5 monoclonal antibody COPD Submitted S:Nov17 fluticasone furoate glucocorticoid agonist long-acting beta2 asthma III vilanterol agonist muscarinic acetylcholine antagonist umeclidinium mepolizumab interleukin 5 IL5 monoclonal antibody hypereosinophilic syndrome III mepolizumab interleukin 5 IL5 monoclonal antibody nasal polyposis III nemiralisib phosphatidylinositol 3-kinase delta PI3K inhibitor COPD acute and chronic II danirixin chemokine C-X-C Motif receptor 2 CXCR2 COPD II antagonist oral 2586881 recombinant human angiotensin converting acute lung injury II enzyme 2 rhACE2 2862277 tumour necrosis factor receptor-1 TNFR1 acute lung injury II domain antibody 2245035 toll-like receptor 7 TLR7 agonist asthma II nemiralisib phosphatidylinositol 3-kinase delta PI3K inhibitor activated PI3K delta syndrome II 3772847 interleukin 33r IL33r monoclonal antibody severe asthma II 2586881 recombinant human angiotensin converting pulmonary arterial hypertension I enzyme 2 rhACE2 252 GSK Annual Report 2017 Pipeline, products and competition continued Pharmaceuticals and Vaccines product development pipeline continued Achieved regulatory review milestones Compound Type Indication Phase MAA NDA BLA Respiratory continued 3008348 alpha V beta 6 integrin antagonist idiopathic pulmonary fibrosis I nemiralisib phosphatidylinositol 3-kinase delta bronchiectasis I PI3K inhibitor 2292767 phosphatidylinositol 3-kinase delta COPD I PI3K inhibitor 3511294 interleukin 5 IL5 long-acting asthma I monoclonal antibody Oncology 3377794 NY-ESO-1 autologous engineered sarcoma, multiple myeloma, non-small cell lung cancer, II TCR-T cells engineered TCR melanoma and ovarian cancer 2857916 B-cell maturation antigen antibody multiple myeloma II drug conjugate 525762 BET family bromodomain inhibitor solid tumours and haematological malignancies I 3174998 OX40 agonist monoclonal antibody solid tumours and haematological malignancies I 3326595 protein arginine methyltransferase 5 cancer I PRMT5 inhibitor 3359609 induced T-cell costimulator ICOS cancer I agonist antibody 1795091 toll-like receptor 4 TLR4 agonist cancer I 2636771 phosphatidylinositol 3-kinase PI3K beta castration resistant prostate cancer I inhibitor Immuno-inflammation Benlysta B lymphocyte stimulator monoclonal systemic lupus erythematosus Approved A: Nov17 A: Jul17 antibody s. c. 3196165 granulocyte macrophage colonyosteoarthritis II stimulating factor monoclonal antibody 3196165 granulocyte macrophage colonyrheumatoid arthritis II stimulating factor monoclonal antibody Benlysta Rituxan B lymphocyte stimulator monoclonal Sjogrens syndrome II antibody s. c. cluster of differentiation 20 CD20 monoclonal antibody i. v. 2982772 receptor-interacting protein 1 RIP1 psoriasis II kinase inhibitor 2982772 receptor-interacting protein 1 RIP1 rheumatoid arthritis II kinase inhibitor 2330811 oncostatin M OSM monoclonal antibody systemic sclerosis II 2982772 receptor-interacting protein 1 RIP1 ulcerative colitis II kinase inhibitor 2831781 lymphocyte activation gene 3 LAG3 autoimmune disease I protein monoclonal antibody 2983559 receptor-interacting protein 2 RIP2 inflammatory bowel diseases I kinase inhibitor 3335065 Kynurenine 3-monooxygenase inhibitor acute pancreatitis I Future pipeline optionality daprodustat 1278863 prolyl hydroxylase inhibitor oral anaemia associated with chronic renal disease III dezamizumab serum amyloid P component SAP amyloidosis II 2398852 monoclonal antibody SAP depleter 2315698 CPHPC oxytocin inhaled oxytocin postpartum hemorrhage II tapinarof 2894512 non-steroidal anti-inflammatory topical atopic dermatitis II tapinarof 2894512 non-steroidal anti-inflammatory topical psoriasis II 2881078 selective androgen receptor modulator muscle wasting I Following a strategic review in 2017, assets from the Rare Diseases Unit are no longer included in the pipeline table with the future ownership of these assets in consideration.
253 GSK Annual Report 2017 Strategic report Governance and remuneration Financial statements Investor information Pharmaceuticals and Vaccines product development pipeline continued Achieved regulatory review milestones Compound Type Indication Phase MAA NDA BLA Vaccines Shingrix recombinant Herpes Zoster prophylaxis Approved S: Nov16 A: Oct17 Zoster Vaccine US Submitted EU Rotavirus live attenuated, PCV Rotavirus prophylaxis III Porcine circovirus free MMR live attenuated measles, mumps, rubella prophylaxis III US Ebola recombinant viral vector Ebola haemorrhagic fever prophylaxis II S. pneumoniae next recombinant conjugated Streptococcus pneumoniae disease prophylaxis II generation COPD recombinant reduction of the frequency of moderate and severe II acute exacerbations in COPD patients by targeting non-typeable Haemophilus influenzae and Moraxella catarrhalis Hepatitis C heterologous recombinant viral vectors hepatitis C virus prophylaxis: prevention of II establishment of chronic infection Malaria next generation recombinant malaria prophylaxis Plasmodium falciparum II Men ABCWY recombinant conjugated meningococcal A, B, C, W and Y disease prophylaxis II in adolescents Shigella conjugated and outer membrane Shigella diarrhea prophylaxis II Tuberculosis recombinant tuberculosis prophylaxis II RSV  recombinant respiratory syncytial virus prophylaxis in paediatric II viral vector population Flu universal universal inactivated influenza vaccine Flu infection prophylaxis with broad protection I II over multiple seasons HIV recombinant proteins HIV infection prophylaxis II Brand names appearing in italics are trade marks owned by or licensed to the GSK group of companies, with the exception of Rituxan owned by Biogen MA Inc. 254 GSK Annual Report 2017 Pipeline, products and competition continued Pharmaceuticals products, competition and intellectual property 3 Patent expiry dates Major Products Compounds Indication s competitor brands US EU Respiratory Anoro Ellipta umeclidinium bromide COPD Respimat, Stiolto 2027 2029 vilanterol trifenatate Utibron Ultibro NCE NCE Breezhaler, 2027-2030 2022-2025 Duaklir Genuair device device Bevespi formulation formulation Arnuity Ellipta fluticasone furoate asthma Qvar, Pulmicort 2021 NA Asmanex, Alvesco NCE 2027-2030 device formulation 2 Avamys Veramyst fluticasone furoate rhinitis Nasonex 2021 2023 Flixotide Flovent fluticasone propionate asthma COPD Qvar, Singulair expired expired Diskus device Diskus device 1 2018-2026 expired HFA-device HFA-device Incruse Ellipta umeclidinium bromide COPD Spiriva Handihaler 2027 2029 Respimat, Eklira Genuair NCE NCE Seebri Breezhaler 2027-2030 2022-2025 device device formulation formulation 4 4 Nucala mepolizumab severe eosinophilic asthma, EGPA Xolair, Cinqair, Fasenra expired 2020 Relvar Breo Ellipta fluticasone furoate asthma COPD Symbicort, Foster, 2025 2027 vilanterol trifenatate Flutiform, Dulera NCE NCE 2027-2030 2022-2025 device device formulation formulation Seretide Advair salmeterol xinafoate asthma COPD Symbicort, Foster, expired expired fluticasone propionate Flutiform, Dulera Diskus device Diskus device 2018-2026 expired HFA-device HFA-device Serevent salmeterol xinafoate asthma COPD Foradil, Striverdi, expired expired Respimat, Onbrez Diskus device Diskus device Breezhaler 2021 HFA-device Trelegy Ellipta fluticasone furoate COPD Trimbow 2027 2029 vilanterol trifenatate NCE NCE umeclidinium bromide 2027-2030 2022-2025 device device formulation formulation Ventolin HFA albuterol sulphate asthma COPD generic companies 2018-2026 expired HFA-device HFA-device Anti-virals Valtrex valaciclovir genital herpes, coldsores, shingles Famvir expired expired Central nervous system Lamictal lamotrigine epilepsy, bipolar disorder Keppra, Dilantin expired expired Imigran Imitrex sumatriptan migraine Zomig, Maxalt, Relpax expired expired Seroxat Paxil paroxetine depression, various anxiety Effexor, Cymbalta, expired expired disorders Lexapro Cardiovascular and urogenital Avodart dutasteride benign prostatic hyperplasia Proscar, Flomax, expired expired finasteride 2 Coreg CR carvedilol phosphate mild-to-severe heart failure, Toprol XL 2026 NA hypertension, left ventricular formulation dysfunction post MI Anti-bacterials Augmentin amoxicillin clavulanate common bacterial generic products NA expired potassium infections 1 See Note 45 to the financial statements, Legal proceedings.
3 Includes Supplementary Protection Certificates which were granted in multiple countries in EU and patent term extensions granted in the US.
4 Data exclusivity expires 2025 EU and 2027 US.
255 GSK Annual Report 2017 Strategic report Governance and remuneration Financial statements Investor information Pharmaceutical products, competition and intellectual property continued 3 Patent expiry dates Major Products Compounds Indication s competitor brands US EU Rare diseases Volibris ambrisentan pulmonary hypertension Tracleer, Revatio NA 2020 Immuno-inflammation Benlysta, Benlysta SC belimumab systemic lupus erythematosus 2025 2026 HIV 1,2 Epzicom Kivexa lamivudine and abacavir HIV AIDS Truvada, Atripla expired 2019 Descovy, Genvoya combination Odefsey Juluca dolutegravir, rilpivitine HIV AIDS Genvoya, Odefsey 2027 2029 Descovy, Atripla NCE NCE Lexiva Telzir fosamprenavir HIV AIDS Prezista, Kaletra, expired 2019 Reyataz NCE Selzentry Celsentri maraviroc HIV AIDS Isentress, Intelence, 2021 2022 Prezista NCE NCE 1 Tivicay dolutegravir HIV AIDS Isentress, Prezista 2027 2029 Reyataz, Kaletra, NCE NCE Biktarvy Triumeq dolutegravir, lamivudine HIV AIDS Atripla, Descovy, 2027 2029 and abacavir Odefsey, Genvoya, NCE NCE Biktarvy Vaccines products, competition and intellectual property 3 Patent expiry dates Major Products Compounds Indication s competitor brands US EU Bexsero meningococcal group-B Meningitis group B prevention Trumenba 2027 2028 vaccine Boostrix diphtheria, tetanus, acellular diphtheria, tetanus, acellular Adacel expired expired pertussis Pertussis booster vaccination Infanrix Hexa Pediarix diphtheria, tetanus, pertussis, Prophylaxis against diphtheria, Pentacel, Pediacel, 2018 expired polio, hepatitis B, Haemophilus tetanus, pertussis, polio, Pentaxim, Pentavac, influenzae type B EU hepatitis B, Haemophilus Hexaxim, Hexyon influenzae type B EU Vaxelis Cervarix HPV 16 & 18 virus like human papilloma virus Gardasil Silgard 2020 2020 particles VLPs, AS04 type 16 and 18 adjuvant MPL aluminium hydroxide Fluarix Tetra split inactivated influenza seasonal influenza prophylaxis Intenza, Flumist QIV, 2022 2022 antigens 2 virus subtypes A Vaxigrip QIV, and 2 subtype B Fluzone QIV, Fluzone High Dose FluLaval split inactivated influenza seasonal influenza prophylaxis Vaxigrip, Mutagrip, 2022 2022 antigens 2 virus subtypes A Fluzone, Influvac, and 2 subtype B Aggripal, Fluad, Intenza, Flumist Menveo meningococcal group A, C, WMeningitis group A, C, W-135 Nimenrix, Menactra 2025 2025 135 and Y conjugate vaccine and Y prophylaxis Prepandrix derived split inactivated pandemic H5N1 influenza Aflunov, Vepacel 2026 influenza virus antigen, prophylaxis AS03 adjuvant a, b 4 Priorix, Priorix Tetra live attenuated measles, mumps, measles, mumps, rubella and MMR II M-M-RVaxPro 2019 expired b Varilrix rubella and varicella vaccine chickenpox prophylaxis Proquad, Varivax Rotarix Human rotavirus RIX4414 strain Rotavirus prophylaxis Rotateq 2020 Synflorix conjugated pneumococcal Prophylaxis against invasive Prevenar Prevnar NA 2024 polysaccharide disease, pneumonia, acute otitis media Shingrix zoster vaccine herpes zoster Zostavax 2026 2026 recombinant, adjuvanted shingles 1 See Note 45 to the financial statements, Legal proceedings.
4 Refers to Priorix and Priorix Tetra, as all patents on Varilrix have expired.
2 Generic competition commenced in many markets during 2016. a Related compounds indications are measles, mumps and rubella vaccine prophylaxis 3 Includes Supplementary Protection Certificates which were granted in b Related compound is varicella vaccine multiple countries in EU and patent term extensions granted in the US.
256 GSK Annual Report 2017 Pipeline, products and competition continued Consumer Healthcare products and competition Brand Products Application Markets Competition Wellness Respiratory Otrivin nasal spray nasal decongestant Germany, Poland, Afrin, Merck Russia, Sweden, Ukraine Nasivin, Merck Theraflu tablets and syrups cold and flu relief Russia, Poland, Ukraine, Tylenol Cold & Flu, US Johnson & Johnson Mucinex, Reckitt Benckiser Lemsip, Reckitt Benckiser Flonase nasal spray allergy relief US Claritin, Bayer, Nasacort, Sanofi Flixonase, Piriton nasal spray, tablets allergy relief UK, Ireland Benadryl, Johnson & Johnson Nicorette US, lozenges, gum and trans-dermal treatment of nicotine withdrawal global Nicorette, Johnson & Johnson NicoDerm, patches as an aid to smoking reduction NiQuitin, Perrigo Nicotinell and cessation ex.
Australia Pain relief Panadol and tablets, caplets, infant paracetamol-based treatment global except US Advil, Pfizer Panadol Cold syrup drops for headache, joint pain, fever, Aspirin, Bayer & Flu cold symptoms Tylenol, Johnson & Johnson Voltaren topical gel non-steroidal, diclofenac based global except US Advil, Pfizer anti-inflammatory Aspirin, Bayer Tylenol, Johnson & Johnson Other ENO effervescent immediate relief antacid global except US Estomazil, Hypermarca Gelusil, Pfizer Tums chewable tablets immediate relief antacid US Alka-Seltzer, Bayer Gaviscon, Reckitt Benckiser Rolaids, Sanofi Oral health Sensodyne, toothpastes, toothbrushes, relief of dentinal hypersensitivity.
global Colgate Sensitive Pro-Relief, Pronamel mouth rinse Pronamel additionally protects Colgate-Palmolive against acid erosion Elmex, Colgate-Palmolive Oral B, Procter & Gamble parodontax toothpaste, medicated helps prevent bleeding gums, Germany, Ireland Colgate Total Gum Health, Corsodyl mouthwash, gel and spray treats and prevents gingivitis Italy, United Kingdom Colgate-Palmolive Yunnan Baiyao, State Enterprise China Polident, denture adhesive, denture improve retention and comfort global Fixodent and Kukident, Poligrip, cleanser of dentures, cleans dentures Procter & Gamble, Corega Steradent, Reckitt Benckiser Aquafresh toothpastes, toothbrushes aids prevention of dental cavities, global Colgate, Colgate-Palmolive mouthwashes maintains healthy teeth, gums Crest, Procter & Gamble and fresh breath Oral-B, Procter & Gamble Skin health Zovirax topical cream and lip care to treat and prevent global Compeed, Johnson & Johnson Abreva non-medicated patch the onset of cold sores Carmex, Carma Labs Blistex, Blistex Incorporated retail own label Nutrition Horlicks malted drinks and foods nutritional Indian sub-continent, Bournvita, Mondelez beverages & food United Kingdom, Ireland Complan, Heinz
